Financial Performance - Revenue for the year ending December 31, 2025, was RMB 4,815.07 million, an increase of 19.81% compared to the previous year[3]. - Gross profit reached RMB 3,685.40 million, reflecting a growth of 20.49% year-over-year[3]. - EBITDA was RMB 1,125.21 million, up RMB 332.84 million from RMB 792.38 million in the previous year[3]. - Net profit attributable to equity holders was RMB 272.44 million, a significant increase of RMB 479.87 million from a loss of RMB 207.43 million in the previous year[3]. - Basic earnings per share were RMB 0.56, while diluted earnings per share were RMB 0.55[3]. - Total revenue for the year ended December 31, 2025, was RMB 4,815,065,000, an increase from RMB 4,018,905,000 in 2024, representing a growth of approximately 19.8%[76]. - Gross profit for the same period was RMB 3,685,395,000, compared to RMB 3,058,631,000 in 2024, indicating a gross margin improvement[76]. - Net profit for the year was RMB 270,034,000, a significant increase from RMB 24,803,000 in 2024, reflecting a growth of over 1,087%[78]. - The company reported total comprehensive income of RMB 262,367,000 for the year, up from RMB 25,636,000 in the previous year[79]. - The company generated substantial operating cash flow, which supports ongoing investments in R&D, production, and marketing[75]. - The company reported a foreign exchange loss of RMB 7,667,000 due to currency fluctuations affecting its overseas subsidiaries[79]. - The company aims to enhance its product portfolio and expand market share through continuous innovation and development efforts[75]. - The company reported a net profit of RMB 272,442,000 for the year, which includes a foreign exchange loss of RMB 7,363,000[84]. - The company’s total comprehensive income for the year includes a special dividend declared by a subsidiary amounting to RMB 584,431,000[84]. Research and Development - The pharmaceutical industry in China is experiencing strong growth driven by economic recovery and policy support, with a focus on innovative drug development[4]. - The company has over 150 approved drugs and has launched 4 innovative drugs, with 50 innovative drugs in development, of which more than 10 are in Phase II or III clinical trials[14]. - The company employs nearly 1,000 R&D personnel, including scientists with extensive experience in multinational pharmaceutical companies[14]. - The company is focusing on core therapeutic areas and has established a competitive innovative drug pipeline through self-innovation strategies[14]. - The company has established an advanced AI-driven model to enhance its innovation capabilities in drug development[14]. - The company plans to accelerate the R&D and commercialization of innovative drugs and biopharmaceuticals to enhance long-term growth[119]. - For the fiscal year ending December 31, 2025, the group reported a total R&D expenditure of RMB 648.69 million, a decrease of 26.92% compared to the same period last year[124]. - The company aims to enhance its core competitiveness and shareholder returns by focusing on R&D, production, and commercialization of innovative drugs and generics[145]. Market and Product Development - The introduction of a commercial health insurance catalog for innovative drugs includes 19 high-priced innovative drugs, marking a significant policy shift[8]. - The number of innovative drugs approved in China has reached a historical high, indicating a shift from "catching up" to "leading" in drug development capabilities[10]. - Internationalization of Chinese innovative drug companies is accelerating, with a notable increase in overseas licensing deals and a shift towards independent commercialization[11]. - The company has successfully submitted a Biologics License Application (BLA) for insulin injection in the U.S. and has achieved overseas licensing for one innovative drug[14]. - The company is developing a triple therapy for hepatitis B, combining siRNA, ASO, and immune regulators to achieve functional cure[30]. - The company is focused on creating a "AI + pharmaceutical" research ecosystem to benefit global patients through innovative drug development strategies[54]. - The company aims to enhance its global capital market position and business flexibility through more agile financing methods, aspiring to become a leading pharmaceutical listed company[149]. Financial Position and Assets - Total assets increased to 7,342,070 thousand RMB from 6,952,754 thousand RMB, representing a growth of approximately 5.6%[82]. - The company's cash and cash equivalents stood at 1,486,796 thousand RMB, slightly up from 1,480,810 thousand RMB, indicating a stable liquidity position[82]. - Total liabilities rose to 6,037,850 thousand RMB from 4,814,251 thousand RMB, marking an increase of approximately 25.3%[82]. - The company's current liabilities increased to 3,197,746 thousand RMB from 2,196,225 thousand RMB, which is a significant rise of about 45.6%[82]. - The company’s total liabilities decreased, indicating improved financial stability and reduced risk exposure[83]. - The total assets of the group as of December 31, 2025, amounted to RMB 11,992.74 million, with total liabilities of RMB 7,654.76 million and equity attributable to shareholders of RMB 4,337.98 million[130]. Awards and Recognition - The group was recognized in the "2025 China Pharmaceutical R&D Strength Ranking TOP 100," highlighting its innovation capabilities in the pharmaceutical industry[60]. - The group received the "2025 China Pharmaceutical Industry Comprehensive Competitiveness Top 100" award, emphasizing its leadership in pharmaceutical R&D and sustainable development[60]. - The group was awarded the "2025 Innovative Value Listed Company" award, recognizing its role in leading industry innovation and future trends[63]. - The group received the 25th China Patent Gold Award for its invention patent on "Phosphate Oseltamivir Granules and Their Preparation Method," recognizing its innovation in the field[59]. Corporate Governance - The company has maintained high standards of corporate governance and complied with all applicable corporate governance codes during the reporting period[156]. - The audit committee has reviewed the company's annual performance announcement and the consolidated financial statements prepared in accordance with international financial reporting standards[159]. - The annual performance announcement is published on the Hong Kong Stock Exchange's disclosure website and the company's website[160]. - The executive directors include Dr. Zhang Yingjun and Dr. Li Wenjia, while the non-executive directors consist of several individuals including Mr. Zhang Yushua and Mr. Tang Xinfang[160].

董事會會議通知 廣東東陽光藥業股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈， 董事會會議將於二零二六年三月三十一日（ 星期二 ）舉行，藉以（ 其中包括 ）審議及 批准本公司及其附屬公司截至二零二五年十二月三十一日止年度的年度業績及其 發佈，以及考慮派付末期股息（ 如有 ）。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或倚賴該等內容而引致之任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 於 本 公 告 日 期 ， 執 行 董 事 為 張 英 俊 博 士 及 李 文 佳 博 士 ， 非 執 行 董 事 為 張 寓 帥 先 生、唐新發先生、朱英偉先生、曾學波先生、東曉維女士及王蕾女士，以及獨立 非執行董事為李新天博士、馬大為博士、尹航博士、林愛梅博士及葉濤 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或倚賴該等內容而引致之任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 盈利預喜 本公告乃由廣東東陽光藥業股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據《香港聯合交易所有限公司證券上市規則》第13.09條及香港法例第571章 證券及期貨條例第XIVA部項下內幕消息條文作出。 本公司董事會（「董事會」）謹此知會本公司股東及潛在投資者，基於本集團目前可 得的未經審核管理賬目及本公司管理層的初步估算，截至二零二五年十二月三十 一日止年度，本集團預期錄得歸母淨利潤約為人民幣2.7億元，相較去年同期錄得 歸母淨虧損約為人民幣2.1億元增加約228.57 %。 預期上述增加主要由於二零二五年下半年流感疫情同比顯著高發，本集團核心 ...

致：香港交易及結算所有限公司 公司名稱: 廣東東陽光藥業股份有限公司 呈交日期: 2026年3月3日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06887 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 112,712,832 | RMB | | 1 | RMB | | 112,712,832 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 112,712,832 | RMB | | 1 | RMB | | 112,712,832 | | 2. 股份分類 ...

Core Viewpoint - Dongyangguang Pharmaceutical (06887.HK) has received acceptance from the National Medical Products Administration for its clinical trial application of the monoclonal antibody drug HEC-648 targeting the Nipah virus G protein, with Phase I clinical research expected to start in 2026 [1] Group 1 - HEC-648 is a fully human monoclonal antibody derived from research at the Wuhan Institute of Virology, aimed at treating Nipah virus infections [1] - The drug has shown a 100% protective rate against preventive death and over 80% therapeutic death protection in animal model trials [1] - HEC-648 is the first and only drug in China to enter the clinical registration phase specifically targeting the Nipah virus [1] Group 2 - The company signed a collaboration agreement with the Wuhan Institute of Virology at the end of 2023 to develop HEC-648 as a Class 1 innovative drug [1] - The mechanism of action of HEC-648 is precise, making it particularly suitable for post-exposure prevention and treatment of Nipah virus infections compared to traditional antiviral drugs [1]

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has submitted a clinical trial application for the monoclonal antibody drug HEC-648 targeting Nipah virus G protein, which has been officially accepted by the Center for Drug Evaluation of the National Medical Products Administration of China, with Phase I clinical research expected to start in 2026 [1] Group 1 - The company is committed to the mission of "scientific creation of new drugs, quality health life" and has initiated the development of Nipah virus antibody drugs as a strategic reserve [1] - The development of this antibody drug is part of the company's strategy to address emerging infectious diseases and to enhance national biosecurity and public health defenses [1] - This initiative supports the "integrated health" strategy and aims to improve the autonomy of core pharmaceutical technologies and the global governance discourse on public health [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 二 、尼帕病毒抗體藥物進展 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） SUNSHINE LAKE PHARMA CO., LTD. 自願性公告 靶向尼帕病毒G蛋白的單克隆抗體新藥HEC -648注射液 臨床試驗申請 獲中國國家藥品監督管理局受理 本 公 告 由 廣 東 東 陽 光 藥 業 股 份 有 限 公 司（ 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）自 願 刊 發。 二零二六年二月二十四日，中國國家藥品監督管理局藥品審評中心（「藥品審評中 心」）正式 受 理本 集 團 提交 的 靶向 尼 帕病 毒 G 蛋白 的 單克 隆 抗體 新 藥HEC -648 注 射 液臨床試驗申請，預計將於二零二六年正式啟動I期臨床研究。 一 、尼帕病毒介紹 尼帕病毒 ...

Recent Events - The approval of the generic drug Fumaric Acid Vonoprazan Tablets, originally developed by Takeda Pharmaceutical, is set for January 30, 2026, and is expected to prepare for market expansion after the patent expiration on August 29, 2026. Currently, 39 companies have been approved for this product, indicating potential price competition post-patent expiration [1] - The original drug's market share may decline rapidly after patent expiration, leading to significant downward pressure on generic drug prices, raising concerns about the long-term profitability of the company [1] Product Development Progress - The first innovative drug, Injection Imatinib, is expected to receive domestic approval by 2026, with three additional drugs recognized as breakthrough therapies anticipated to launch between 2027 and 2028 [2] - The BLA approval for Insulin Glargine in the U.S. market is expected to be completed in the first half of 2026, while Insulin Aspart is planned for approval by the end of 2026, aiding international expansion [2] - In January 2026, the SGLT-2 inhibitor Ologliptin Capsules were approved for market release, and the company has partnered with Crystal Technology to develop an AI drug research platform, which is expected to catalyze short-term growth [2] Business and Technical Development - In January 2026, the company launched an AI-driven research platform focused on the PROTAC mechanism, integrating clinical pipeline data, with the first AI-driven small molecule drug HEC169584 entering clinical Phase I [3] - The company is accelerating internationalization through overseas business development partnerships, such as a nearly $1 billion licensing agreement with UK-based Apollo for the HEC88473 project in November 2024 [4] Company Structure and Governance - In August 2025, the company completed its listing on the Hong Kong Stock Exchange through the absorption and merger of Dongyangguang Changjiang Pharmaceutical, achieving overall listing of its pharmaceutical assets [5] - The actual controller changed to Zhang Yushuang in December 2025, with market attention on how the new leadership will drive strategic transformation [6] Industry and Risk Analysis - The company has a high dependency on its core product, Oseltamivir Phosphate (Kewai), which accounted for over 60% of revenue in the first half of 2025, necessitating attention to single product risks and the impact of centralized procurement [7] - The sentiment in the biopharmaceutical sector has been weak recently, with the A-share biopharmaceutical index declining by 3.52% over the past 20 days, and southbound funds reducing holdings by 38,060 shares [8]

Company Overview - Dongyang Sunshine Pharmaceutical (东阳光药) received approval for Fumaric Acid Vonoprazan Tablets on January 30, 2026, leading to stock price fluctuations influenced by product approval and market expectations regarding competition and profitability [1] - The company's core product, Oseltamivir Phosphate (可威), is expected to account for over 60% of revenue in the first half of 2025, but is projected to decline by 37.1% in 2024 due to procurement issues [4] Industry Analysis - The generic drug market is highly competitive, with 39 companies already approved for the same product and an additional 69 companies under review, indicating potential price wars and profit margin compression post-patent expiration [3] - Takeda Pharmaceutical currently holds a monopoly in the market, but its market share is expected to decline rapidly after the patent protection period ends on August 29, 2026, leading to downward pressure on generic drug prices [3] Financial Performance - The company's price-to-earnings ratio (TTM) is negative at -57.55, reflecting ongoing profitability challenges [4] - On February 12, during a stock price drop, trading volume surged to 20.49 million HKD, indicating increased market volatility and diverging opinions among investors [4] Market Trends - The biopharmaceutical sector has seen a decline, with the A-share biopharmaceutical index dropping by 3.52% over the past 20 days, while the Hong Kong Hang Seng Index fell by 1.72%, suggesting weak industry sentiment [5] - Over the last 20 trading days, southbound funds have seen a net reduction of 38,060 shares, indicating short-term pressure on capital [6]

Core Viewpoint - The report from Guolian Minsheng Securities highlights the synergistic effects of small nucleic acid drugs and GLP-1 class drugs in the weight loss sector, suggesting they could become a "golden duo" for weight management [1][4]. Group 1: Drug Efficacy and Development - Arrowhead has reported promising initial weight loss results from two small nucleic acid drugs targeting INHBE and ALK7, with ARO-INHBE showing an average fat reduction of 9.9% and liver fat reduction of up to 38.6%, alongside a 3.6% increase in lean tissue [1]. - ARO-ALK7 demonstrated a dose-dependent average reduction of ALK7 mRNA by 88%, confirming the TRiM platform's ability to inhibit fat cell gene expression [1]. - Wave Life's WVE-007 targeting liver INHBE showed a 9.4% reduction in visceral fat and a 4.5% overall fat reduction after three months, with a 3.2% increase in lean body mass [3]. Group 2: Market Trends and Collaborations - Major pharmaceutical companies are increasingly investing in small nucleic acid drugs, with Eli Lilly committing $1.2 billion in collaboration with Saint Inbiotech for RNAi candidate drug development for metabolic diseases [3]. - Eli Lilly also invested $1 billion in HAYA's lncRNA platform for obesity and related metabolic disease treatments, while Novo Nordisk partnered with Replicate Bioscience for a $550 million project targeting obesity and type 2 diabetes [3]. - The speed of Chinese pharmaceutical companies in developing small nucleic acid drugs for weight loss is nearly on par with international counterparts, with several companies like Hengrui Medicine and Innovent Biologics actively pursuing this area [5]. Group 3: Investment Recommendations - The report suggests focusing on companies involved in small nucleic acid weight loss targets, including Hengrui Medicine, Chengdu Xian Dao, China National Pharmaceutical Group, East China Pharmaceutical, and others [6].